NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

In a recent regulatory review, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard ...

Premier Doug Ford called the expansion of Eisai Inc. in Mississauga “a major milestone in strengthening our plan to build ...

And more pharma news updates from Pharmalittle.

Eisai estimated the number of U.S. patients eligible for the drug would reach around 100,000 within three years, increasing gradually from there over the medium to long term.

The study, in the New England Journal of Medicine, found that a drug developed by Tokyo-based Eisai and Cambridge, Mass.-based Biogen reduced a key marker of Alzheimer’s disease, the amyloid ...

Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review. Hotspots ranked Start the day smarter ...

Ivan Cheung, chairman and CEO of Eisai Inc. When speaking to people living with Alzheimer’s disease and their loved ones, the first thing I tell them is that I am sorry it has taken so long to ...

Eisai and Biogen hope the long-term data, presented at the Alzheimer’s Association International Conference, will boost global adoption of Leqembi, which was approved by the Food and Drug ...

CNW/ - Eisai Limited, a leading research and development-based pharmaceutical company specializing in neurology and oncology, ...

Eisai is hoping to present enough evidence to the FDA to convince regulators that the benefit of treatment with lecanemab outweighs the risks and avoid a warning on the drug’s potential label.

Eisai and Biogen sought the Food and Drug Administration’s accelerated approval for the amyloid beta-busting drug, lecanemab. Sold under the brand name Leqembi, the drug is priced at $26,500 per ...